Heart failure resulting from myocardial infarction(MI)is a leading global health concern.Current revasculari-zation therapies cannot fully restore the infarcted myocardium or prevent maladaptive ventricular remodeling...Heart failure resulting from myocardial infarction(MI)is a leading global health concern.Current revasculari-zation therapies cannot fully restore the infarcted myocardium or prevent maladaptive ventricular remodeling.Traditional Chinese medicine with its multitarget regulation and favorable biosafety shows a promising thera-peutic potential.Tanshinone IIA(TIIA)and formononetin(FM),two bioactive compounds derived from Salvia miltiorrhiza and Astragalus membranaceus,respectively,exhibit antioxidant,anti-inflammatory,and proangio-genic effects.Herein,a neutrophil-targeted nanomedicine(TF-5NP)was developed to deliver TIIA and FM to the infarcted myocardium for mitigating oxidative damage and promoting angiogenesis.TF-5NP was synthesized by coassembling bis-5-hydroxytryptamine-modified 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly-ethylene glycol-carboxylic acid with cholesterol and lipid 1,2-distearoyl-sn-glycero-3-phosphoglycerol,which binds to troponin in the infarcted myocardium.This nanomedicine reduces inflammation and cardiomyocyte damage and improves cardiac function in porcine MI models,with therapeutic effects lasting for~28 d.These findings suggest that TF-5NP use is a promising approach for treating post-MI maladaptive remodeling and heart failure.展开更多
基金supported by the National Natural Science Founda-tion of China(Grant Nos.82274271&82104962&82004112)Guang-dong Basic and Applied Basic Research Foundation(Grant Nos.2024B1515020033&2024A1515011686&2023A1515220029)+6 种基金Outstanding Young Talents Youth Program of Guangdong Hospital of Chinese Medicine(Grant No.SZ2023QNO1)Guangzhou Science and Technology Fund(202201020565)Major Science and Technology Projects of Chinese Medicine in Guangzhou Region(2025CX010,2025QN010)the 2023 Young Top Talent Cultivation“Unveiling the List of Commander-in-Chief”Project Program of Guangzhou University of Chinese Medicine(to Shuai MAO)Project of State Key Laboratory of Dampness Syndrome of Chinese Medicine,The Second Affiliated Hos-pital of Guangzhou University of Chinese Medicine(SZ2024KF01)Guangzhou Science and Technology Plan(2024A04J3304)Guangzhou Municipal Science and Technology Bureau-Academia Joint Funding Program(2024A03J0062).
文摘Heart failure resulting from myocardial infarction(MI)is a leading global health concern.Current revasculari-zation therapies cannot fully restore the infarcted myocardium or prevent maladaptive ventricular remodeling.Traditional Chinese medicine with its multitarget regulation and favorable biosafety shows a promising thera-peutic potential.Tanshinone IIA(TIIA)and formononetin(FM),two bioactive compounds derived from Salvia miltiorrhiza and Astragalus membranaceus,respectively,exhibit antioxidant,anti-inflammatory,and proangio-genic effects.Herein,a neutrophil-targeted nanomedicine(TF-5NP)was developed to deliver TIIA and FM to the infarcted myocardium for mitigating oxidative damage and promoting angiogenesis.TF-5NP was synthesized by coassembling bis-5-hydroxytryptamine-modified 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly-ethylene glycol-carboxylic acid with cholesterol and lipid 1,2-distearoyl-sn-glycero-3-phosphoglycerol,which binds to troponin in the infarcted myocardium.This nanomedicine reduces inflammation and cardiomyocyte damage and improves cardiac function in porcine MI models,with therapeutic effects lasting for~28 d.These findings suggest that TF-5NP use is a promising approach for treating post-MI maladaptive remodeling and heart failure.
